Skip to main content

The use of proteomics for blood biomarker research in premature infants: a scoping review

Abstract

Over the last decade, the use of proteomics in the setting of prematurity has increased and has enabled researchers to successfully identify biomarkers for an array of associated morbidities. The objective of this scoping review was to identify the existing literature, as well as any knowledge gaps related to proteomic biomarker discoveries in the setting of prematurity. A scoping review was conducted using PubMed, Embase and Medline databases following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. The study selection process yielded a total of 700 records, of which 13 studies were included in this review. Most studies used a tandem Mass Spectrometry (MS/MS) proteomics approach to identify key biomarkers. The corresponding studies identified proteins associated with retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), necrotising enterocolitis (NEC), late onset sepsis (LOS) and gestational age. This scoping review demonstrates the limited use of proteomics to identify biomarkers associated with severe complications of prematurity. Further research is warranted to identify biomarkers of other important morbidities associated with prematurity, such as intraventricular haemorrhage (IVH) and cerebral palsy, and to investigate the mechanisms associated with these outcomes.

Introduction

Proteomics is a methodological approach that allows for the analysis of many proteins simultaneously and has been successful in identifying many novel disease biomarkers [1]. Proteomic methodologies have been previously used in varying contexts, such as discovering biomarkers of diabetic nephropathy and identifying novel diagnostic markers of cancer [2, 3]. Plasma proteomics is advantageous as it only uses a small volume of blood to study hundreds and sometimes thousands of proteins, and can identify changes in protein expression that may occur with age and disease [4]. Proteomics is not limited to analysis of blood samples, and enables the use of biological fluids such as saliva and urine, and tissue samples (e.g. tumours) [5]. Due to the small volume required for analysis, plasma proteomics has become increasingly popular and has enabled investigations of plasma proteins in vulnerable populations such as in paediatrics, as well as in critically ill patients, where blood may be scarce and not readily available for research purposes [4].

Preterm birth is the leading cause of death among the paediatric population globally [6]. With major technological advances in neonatal care over the last few decades, there has been an increase in survival of infants born preterm (< 37 weeks’ gestation), in particular those born extremely preterm (< 28 weeks’ gestation) [7]. Despite the technological advances that have improved survival in these vulnerable populations, preterm birth is associated with significant morbidities including intraventricular haemorrhage (IVH), necrotising enterocolitis (NEC), bronchopulmonary dysplasia (BPD), and neurosensory impairments [8].

Within the last decade proteomics has enabled researchers to identify predictive biomarkers of NEC in preterm infants using buccal swabs [9]. More specifically, plasma proteomics has previously identified proteins that may play a role in the development of retinopathy of prematurity [10]. However, to date there has been limited research into plasma protein biomarkers in predicting other outcomes in preterm infants. Consequently, a scoping review was conducted to understand the current state of knowledge in this space, and to identify knowledge gaps that could be addressed by future studies. A preliminary search of MEDLINE, PubMed, JBI Evidence Synthesis and Embase was conducted and did not identify any current systematic reviews or scoping reviews on this topic. Thus, this review is novel and will make a significant contribution to the understanding and knowledge in the use of proteomics in preterm infants.

Review question

The following research question was formulated using the PCC (Population, Concept, Context) framework: What is the existing proteomic evidence of blood biomarker research in the setting of prematurity?

Methods

Study design

This scoping review was conducted based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist [11].

Search strategy

The following three electronic databases: Medline, Embase and PubMed were searched on the 24th September 2020 for all peer-reviewed studies. An additional search for grey literature was conducted using the OpenGrey and GreyLit databases. The specific search terms used for each database are detailed in Appendix A. In summary, studies included in this review were identified using the search terms [‘preterm’ OR ‘premature’) AND [‘proteome’ OR ‘protein-analysis’] AND [‘blood-protein’ OR [biomarker’], as well as including derivatives of these terms. Studies identified in this review were limited to those written in the English language and conducted in humans only. Studies retrieved using these search terms and parameters were screened by two authors (NL and TC), initially focusing on the eligibility of the studies’ titles and abstracts using the following inclusion and exclusion criteria.

Selection criteria

Inclusion criteria: (I) infants born preterm (< 37 weeks), (II) blood proteome assessed, (III) primary research, (IV) English language and (V) human study.

Exclusion criteria: (I) infants born at term or post-term (≥ 37 weeks), (II) proteome of other biological samples (e.g. saliva or urine) assessed, (III) case report, review, conference abstract or editorial correspondence and (IV) animal studies.

Data extraction and charting

Studies that were chosen for full-text assessment were assessed by NL and TC and with any discrepancies and uncertainties, a third reviewer (VI) was to assess the studies. Data extracted included publication year, disease/outcome assessed, aims, study population, comparative groups, proteomic methodology, protein-pathway analysis, key findings and study limitations. The detailed assessment for each critically reviewed study is presented in Table 1.

Table 1 Summary of included studies in the scoping review of proteomics in setting of prematurity

Results

The initial search identified 678 studies using the scoping review search strategy, with an additional 22 studies identified using the grey literature search. After the removal of duplicates, 462 publications remained for title and abstract screening. A vast majority of studies (n = 444, 96%) were excluded due to not fulfilling the inclusion criteria or having no relevance to the topic of prematurity and blood biomarker discoveries. Eighteen studies underwent full-text review, with three studies excluded because they did not primarily investigate biomarkers of disease and outcomes. One study of children born preterm did not collect samples at birth and one study presented data in brief report, which did not include any proteomic data. Figure 1 illustrates the article screening and selection process, following the PRISMA guidelines (Fig. 2).

Fig. 1
figure 1

Summary of the study selection process for the scoping review

Fig. 2
figure 2

Blood proteomic studies identified were primarily conducted in the setting of LOC/NEC (23%, 3 studies) and ROP (15%, 2 studies)

Description of included studies

A total of thirteen studies met the inclusion criteria for this scoping review and are summarised in Table 1. Eleven of the thirteen included studies investigated proteins and their associations with known outcomes of prematurity. The participant gestational age at birth ranged from < 23 to 37 weeks, with sample sizes varying from 4 to 77 participants. Most studies used a tandem Mass Spectrometry method (MS/MS) to analyse the proteins of interest [10, 12,13,14,15]. Three of the fourteen studies also conducted protein validation and completed this task using protein microarray and immunoassay techniques [10, 16, 17]. Approximately half of the studies (n = 7, 47%) were completed using plasma samples (Fig. 3). The proteins identified as proteins of interest across the 13 studies included in this scoping review, with reference to the specific study/ies are summarised in Table 2.

Table 2 Proteins identified in the studies included in this scoping review
Fig. 3
figure 3

Sample types used in the identified studies were primarily conducted using plasma (47%, 7 studies) and serum (40%, 6 studies)

Retinopathy of prematurity (ROP)

Two studies investigated the outcome associated with prematurity, ROP [10, 18]. ROP is seen most commonly among infants born very preterm (< 32 weeks’ gestational age) or < 1250 g birth weight. Abnormal blood vessel development occurs in the retina in response to oxygen exposure, which can lead to retinal detachment and blindness in severe cases [18]. Currently there is no existing method to predict the occurrence of ROP in infants born preterm or born with a low birth weight and all high-risk infants are routinely screened. Hence, a proteomic approach was adopted to identify underlying biomarkers of the disease [10, 18]. Several biomarkers of the complement and inflammatory system were identified in infants who developed ROP [10]. Lynch et al. identified mitochondrial Superoxide dismutase (MnSOD), an antioxidant located in the mitochondria, as a potential therapeutic target for significant ROP [18].

Bronchopulmonary dysplasia (BPD) and pulmonary vascular disease (PVD)

Two of the thirteen included studies investigated plasma proteins and their association with BPD [15, 19]. BPD is a chronic lung disease that affects infants born preterm [20]. Arjaans et al. implemented the use of a SOMAscan proteomic assay, whereas Zasada et al. utilised MS/MS approach to identify key biomarkers of BPD. Both studies identified several proteins that may be used in future diagnosis of BPD as well associations between severity and disease prognosis [15, 19]. Wagner et al. investigated plasma proteins and their association with the pathogenesis of PVD, a term used to describe abnormal function and vascular growth of the lungs. They identified 18 proteins that were associated with PVD, including proteins associated with growth factors, angiogenesis and the extracellular matrix [21]. The protein analysis conducted by Wanger et al. also identified proteins of several different biological process pathways (e.g. Tissue Inhibitor of Metalloproteinases 3 (TIMP-3) used in platelet degradation and Bone proteoglycan II, involved in degradation of the extracellular matrix (ECM)) that may be associated with PVD.

Necrotising enterocolitis (NEC) and late onset sepsis (LOS)

Two of the thirteen studies examined biomarkers for NEC and LOS [12, 16]. Ng et al. investigated biomarkers for the early diagnosis of NEC among preterm infants. Ng et al. investigated their samples with a variety of proteomic methods, which included matrix-assisted laser desorption/ionisation (MALDI-ToF), 2D Gel-Electrophoresis (2DGE). The results of the discovery component of the study were validated using commercially available immunoassay kits and protein microarrays. Ng et al. identified a des-arginine variant of serum amyloid A (SAA) and Proapolipoprotein CII (Pro-apoC2) as very promising biomarkers of late-onset septicaemia and NEC [16]. Stewart et al. investigated the serum and metabolome of preterm infants with NEC and LOS longitudinally with a LC- MS/MS technique. Among all patient groups investigated the proteins and metabolite were comparable, with 12 proteins (e.g. Serum Amyloid A-2 and Haptoglobin) associated with NEC and LOS diagnosis [12]. Interestingly, the only protein common across the two studies was SAA [12, 16].

Gestational age and signalling pathways

Suski et al. completed several studies [13, 14] investigating plasma proteome changes in preterm infants comparing gestational ages [13] and malfunctioning proteins in various signalling pathways [14]. Utilising a tandem MS approach they were able to identify proteomic changes across varying gestational ages for several pathways which include; coagulation, inflammation, complement activations and immunomodulation [13, 14]. Suski et al. also observed Complement C3, Factor V and Complement C4-A were associated with gestational age [13]. LRG1 was the only common protein identified across the two studies [13, 14].

Discussion

In this scoping review we identified 13 primary studies that used proteomics to identify blood protein biomarkers in the setting of prematurity that used either plasma or serum as the sample which was analysed. It is important to note that studies conducted in serum cannot be directly compared to studies conducted in plasma as these are two entirely different samples. Unlike plasma which is prepared only via centrifugation, Preparation of serum entails formation and removal of a blood clot activating not only coagulation proteins but also changing the concentration of inflammatory proteins, a scenario that reflects the manipulation itself and not the physiological setting. Similarly, a cord-blood sample is different to the blood sample collected from babies at birth, due to differences in the vasculature of the umbilical cord and blood vessels within the newborn. Our findings indicate that the focus of research in the setting of blood protein biomarkers in the setting of prematurity focused on several diseases, such as ROP, BPD, LOS and NEC. However, there has been a lack of research focusing into other outcomes known to be associated with preterm birth such as cerebral palsy, intraventricular haemorrhage, or hypertension. To our best knowledge, none of the findings from the studies included in our scoping review have been translated into the clinical setting. Blood proteomic studies within this population may reflect a lack of collaboration between clinicians and proteomic experts, as well as difficulty in accessing samples from premature babies, factors that could be overcome, particularly in research institutes associated with tertiary hospitals [22].

Limitations of current published studies

The main limitation of the studies included in this review are the small sample sizes represented in those studies. Future studies should be adequately powered, and a shift of the primary focus from not only understanding mechanism of disease, but also on  identifying proteins that are associated with outcomes or disease and which can be used in the clinical setting to improve outcomes for premature infants.

Conclusions

This scoping review  identified a paucity of evidence around biomarker discoveries in the population of preterm infants. Several proteomic methods, including tandem mass spectrometry, immunoassays, and MALDI-TOF MS, have been used to identify biomarkers for various outcomes (e.g. ROP and BPD) associated with preterm birth. This review identifies the need for future research focusing on biomarkers to understand the possible mechanisms related to preterm birth, as well as to identify predictive protein biomarkers for complications or long-term sequelae associated with preterm birth, such as intraventricular haemorrhage and hypertension.

Availability of data and materials

Not applicable.

Abbreviations

ROP:

Retinopathy of prematurity

PVD:

Pulmonary vascular disease

PH:

Pulmonary hypertension

LOS:

Late onset sepsis

BPD:

Bronchopulmonary dysplasia

NEC:

Necrotising enterocolitis

GA:

Gestational age

Pro-apoC2:

Proapolipoprotein CII

SAA:

Serum amyloid A

MALDI-TOF MS:

Matrix assisted laser desorption ionization-time of flight mass spectrometry

MnSOD:

Mitochondrial superoxide dismutase

CRDL1:

Chordin-like protein 1

PCSK9:

Proprotein convertase subtilisin/kexin type 9

FGF-19:

Fibroblast growth factor 19

MSP:

Hepatocyte growth factor-like protein

LH:

Luteinizing hormone

IGFBP-7:

Insulin-like growth factor-binding protein 

iTRAQ:

Isobaric tags for relative and absolute quantitation

LC–MS/MS:

Liquid chromatography and tandem mass spectrometry

C1Inh:

C1-inhibitor

SAP:

Serum amyloid P

Apo-D:

Apolipoprotein D

LRG1:

Leucine-rich alpha-2-glycoprotein 1

ZAG:

Zinc-alpha-2-glycoprotein

ORM:

Orosomucoid

MST1:

Macrophage stimulating 1

PF-4:

Platelet factor 4

MST1R:

Macrophage-stimulating protein

APP:

Amyloid precursor protein

STK16:

Serine/threonine-protein kinase 16

CTAP-III:

Connective tissue-activating peptide III

PDGF-AA:

Platelet-derived growth factor AA

VEGF121:

Vascular endothelial growth factor 121

ANG-1:

Angiopoietin 1

ANG-2:

Angiopoietin 2

BMP10:

Bone morphogenetic protein 10

HGF:

Hepatocyte growth factor

PEA:

Proximity extension assays

C3dCR2:

Complement C3d Receptor 2

COLEC12:

Collectin subfamily member 12

INHBC:

Inhibin beta C subunit

SELL:

Selectin L

IL2-RA:

Interleukin 2 Receptor alpha

GP6:

Glycoprotein 6 platelet

GFBP-1:

Insulin-like growth factor-binding protein-1

FSTL3:

Follistatin like 3

GDF15:

Growth differentiation factor 15

CGA:

Glycoprotein hormone alpha polypeptide

ELLSA:

Enzyme-linked immunosorbent assay

MIF:

Macrophage migration inhibitory factor

IUGR:

Intrauterine growth restriction

AGA:

Adequate gestational age

MBOAT7:

Lysophospholipid acyltransferase 7

SUMO3:

Small ubiquitin-related modifier 3

FCN2:

Ficolin-2

TF:

Serotransferrin

PDA:

Patent ductus arteriosus

BNP:

B-type natriuretic peptide

References

  1. Ahram M, Petricoin EF. Proteomics discovery of disease biomarkers. Biomark Insights. 2008;6(3):325–33.

    Google Scholar 

  2. Hanash S, Taguchi A. Application of Proteomics to Cancer Early Detection. Cancer J. 2011;17(6):423–8.

    CAS  Article  Google Scholar 

  3. Merchant ML, Klein JB. Proteomic discovery of diabetic nephropathy biomarkers. Adv Chronic Kidney Dis. 2010;17(6):480–6.

    Article  Google Scholar 

  4. Ignjatovic V, Geyer PE, Palaniappan KK, Chaaban JE, Omenn GS, Baker MS, et al. Mass spectrometry-based plasma proteomics: considerations from sample collection to achieving translational data. J Proteome Res. 2019;18(12):4085–97.

    CAS  Article  Google Scholar 

  5. Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics. 2006;6(23):6326–53.

    CAS  Article  Google Scholar 

  6. Walani SR. Global burden of preterm birth. Int J Gynecol Obstet. 2020;150(1):31–3.

    Article  Google Scholar 

  7. Cheong JLY, Spittle AJ, Burnett AC, Anderson PJ, Doyle LW. Have outcomes following extremely preterm birth improved over time? Semin Fetal Neonatal Med. 2020;25(3):101114.

    Article  Google Scholar 

  8. Glass HC, Costarino AT, Stayer SA, Brett CM, Cladis F, Davis PJ. Outcomes for extremely premature infants. Anesth Analg. 2015;120(6):1337–51.

    Article  Google Scholar 

  9. Murgas Torrazza R, Li N, Young C, Kobeissy F, Chow M, Chen S, et al. Pilot study using proteomics to identify predictive biomarkers of necrotizing enterocolitis from buccal swabs in very low birth weight infants. Neonatology. 2013;104(3):234–42.

    CAS  Article  Google Scholar 

  10. Zasada M, Suski M, Bokiniec R, Szwarc-Duma M, Borszewska-Kornacka MK, Madej J, et al. An iTRAQ-based quantitative proteomic analysis of plasma proteins in preterm newborns with retinopathy of prematurity. Investig Opthalmology Vis Sci. 2018;59(13):5312.

    CAS  Article  Google Scholar 

  11. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467.

    Article  Google Scholar 

  12. Stewart CJ, Nelson A, Treumann A, Skeath T, Cummings SP, Embleton ND, et al. Metabolomic and proteomic analysis of serum from preterm infants with necrotising entercolitis and late-onset sepsis. Pediatr Res. 2016;79(3):425–31.

    CAS  Article  Google Scholar 

  13. Suski M, Bokiniec R, Szwarc-Duma M, Madej J, Bujak-Gizycka B, Kwinta P, et al. Prospective plasma proteome changes in preterm infants with different gestational ages. Pediatr Res. 2018;84(1):104–11.

    CAS  Article  Google Scholar 

  14. Suski M, Bokiniec R, Szwarc-Duma M, Madej J, Bujak-Gizycka B, Borszewska-Kornacka MK, et al. Plasma proteome changes in cord blood samples from preterm infants. J Perinatol Off J Calif Perinat Assoc. 2018;38(9):1182–9.

    CAS  Google Scholar 

  15. Zasada M, Suski M, Bokiniec R, Szwarc-Duma M, Borszewska-Kornacka MK, Madej J, et al. Comparative two time-point proteome analysis of the plasma from preterm infants with and without bronchopulmonary dysplasia. Ital J Pediatr. 2019;45(1):112.

    Article  Google Scholar 

  16. Ng PC, Ang IL, Chiu RWK, Li K, Lam HS, Wong RPO, et al. Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. J Clin Invest. 2010;120(8):2989–3000.

    CAS  Article  Google Scholar 

  17. Ruis-Gonzalez MD, Canete MD, Gomez-Chaparro JL, Abril N, Canete R, Lopez-Barea J. Alterations of protein expression in serum of infants with intrauterine growth restriction and different gestational ages. J Proteomics. 2015;119(101475056):169–82.

    CAS  Article  Google Scholar 

  18. Lynch AM, Wagner BD, Mandava N, Palestine AG, Mourani PM, McCourt EA, et al. The relationship of novel plasma proteins in the early neonatal period with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2016;57(11):5076–82.

    CAS  Article  Google Scholar 

  19. Arjaans S, Wagner BD, Mourani PM, Mandell EW, Poindexter BB, Berger RMF, et al. Early angiogenic proteins associated with high risk for bronchopulmonary dysplasia and pulmonary hypertension in preterm infants. Am J Physiol Lung Cell Mol Physiol. 2020;318(4):L644–54.

    CAS  Article  Google Scholar 

  20. Ramsay PL, DeMAYO FJ, Hegemier SE, Wearden ME, Smith CV, Welty SE. Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;164(1):155–61.

    CAS  Article  Google Scholar 

  21. Wagner BD, Babinec AE, Carpenter C, Gonzalez S, O’Brien G, Rollock K, et al. Proteomic profiles associated with early echocardiogram evidence of pulmonary vascular disease in preterm infants. Am J Respir Crit Care Med. 2018;197(3):394–7.

    CAS  Article  Google Scholar 

  22. Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol. 2017;13(9):942.

    Article  Google Scholar 

  23. Byung MC, Kee HL, Baik LE, Kee HY, Young SH, Chang SS, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics. 2005;115(3):e255–61.

    Article  Google Scholar 

  24. Tosson AMS, Glaser K, Weinhage T, Foell D, Aboualam MS, Edris AA, et al. Evaluation of the S100 protein A12 as a biomarker of neonatal sepsis. J Matern Fetal Neonatal Med. 2020;33(16):2768–74.

    CAS  Article  Google Scholar 

  25. Zhong W, Danielsson H, Tebani A, Karlsson MJ, Elfvin A, Hellgren G, et al. Dramatic changes in blood protein levels during the first week of life in extremely preterm infants. Pediatr Res. 2020. https://doi.org/10.1038/s41390-020-0912-8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

There was no specific funding utilised for this review.

Author information

Authors and Affiliations

Authors

Contributions

All authors listed have made a substantial, direct and intellectual contribution to the work. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Vera Ignjatovic.

Ethics declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appendices

Appendix A: Search strategies

A. 1. PubMed database

  1. 1.

    “Preterm” OR “pre-term” OR “prematur*”

  2. 2.

    “Proteom*” OR “protein-analysis”

  3. 3.

    “Blood-protein*” OR “serum-protein*” OR “plasma-protein*” OR “biomarker*” OR “marker*”

  4. 4.

    1 and 2 and 3

  5. 5.

    (“Animal” OR “animals” OR “rat” OR “rats” OR “mouse” OR “mice” OR “swine” OR “porcine” OR “murine” OR “sheep” OR “lamb” OR “lambs” OR “pig” OR “pigs” OR “piglet” OR “piglets” OR “rabbit” OR “rabbits” OR “cat” OR “cats” OR “dog” OR “dogs” OR “cattle” OR “bovine” OR “monkey” OR “monkeys” OR “trout” OR “marmoset” OR “marmosets”) NOT (“human” OR “humans” OR “patient” OR “patients” OR “newborn*” OR “baby” OR “babies” OR “neonat*” OR “infan*” OR “toddler*” OR “pre-schooler*” OR “preschooler*” OR “kindergarten” OR “boy” OR “boys” OR “girl” OR “girls” OR “child” OR “children” OR “childhood” OR “adolescen*” OR “pediatric*” OR “paediatric*” OR “youth*” OR “teen” OR “teens” OR “teenage*” OR “school-aged*” OR “school-child*” OR “school-girl*” OR “school-boy*” OR “schoolgirl*” OR “schoolboy*” OR “man” OR “men” OR “woman” OR “women” OR “adult” OR “adults” OR “middle-age*” OR “elderly”)

  6. 6.

    5 not 6

  7. 7.

    Limit to English language

A. 2. Embase database

  1. 1.

    Prematurity/

  2. 2.

    Exp low birth weight/

  3. 3.

    (Preterm or pre-term or prematur*).mp.

  4. 4.

    1 or 2 or 3

  5. 5.

    Exp proteomics/

  6. 6.

    Proteome/

  7. 7.

    Exp *protein analysis/

  8. 8.

    Proteom*.tw,kw,dq.

  9. 9.

    5 or 6 or 7 or 8

  10. 10.

    Exp plasma protein/

  11. 11.

    (Blood-protein* or serum-protein* or plasma-protein*).tw,kw,dq.

  12. 12.

    Biological marker/

  13. 13.

    (Biomarker* or marker*).tw,kw,dq.

  14. 14.

    10 or 11 or 12 or 13

  15. 15.

    4 and 9 and 14

  16. 16.

    (Rat or rats or mouse or mice or swine or porcine or murine or sheep or lamb or lambs or pig or pigs or piglet or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset or marmosets).ti. and animal experiment

  17. 17.

    Animal experiment/ not (human experiment/ or human/)

  18. 18.

    Case report/

  19. 19.

    15 and 18

  20. 20.

    LIMIT 15 to (conference abstract or conference paper or "conference review" or editorial or letter)

  21. 21.

    15 not (16 or 17 or 19 or 20)

  22. 22.

    Limit 21 to English language

A. 3. Medline. database

  1. 1.

    Exp infant, low birth weight/ or infant, premature/

  2. 2.

    Exp infant, premature, diseases/

  3. 3.

    Premature Birth/

  4. 4.

    (Preterm or pre-term or prematur*).mp.

  5. 5.

    1 or 2 or 3 or 4

  6. 6.

    Exp Proteomics/

  7. 7.

    Proteome/

  8. 8.

    Proteom*.tw,kf.

  9. 9.

    6 or 7 or 8

  10. 10.

    Exp Blood Proteins/

  11. 11.

    (Blood-protein* or serum-protein* or plasma-protein*).tw,kf.

  12. 12.

    Exp biomarkers/

  13. 13.

    (Biomarker* or marker*).tw,kf.

  14. 14.

    10 or 11 or 12 or 13

  15. 15.

    5 and 9 and 14

  16. 16.

    (Exp animals/ or (rat or rats or mouse or mice or swine or porcine or murine or sheep or lamb or lambs or pig or pigs or piglet or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset or marmosets).ti.) not human*.sh.

  17. 17.

    Limit 15 to (case reports or comment or editorial or guideline or letter or practice guideline)

  18. 18.

    15 not (16 or 17)

  19. 19.

    Limit 18 to English language

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Letunica, N., Cai, T., Cheong, J.L.Y. et al. The use of proteomics for blood biomarker research in premature infants: a scoping review. Clin Proteom 18, 13 (2021). https://doi.org/10.1186/s12014-021-09316-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12014-021-09316-y

Keywords

  • Proteomics
  • Biomarkers
  • Premature Infants
  • Prematurity